Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Abt-724. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.83 |
| ▸ | DRD4 | P21917 | 18/20 | 0.85 |
| ▸ | DRD2 | P14416 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.83 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.83 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-724 SCHEMBL1448486 | 0.92 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL29406160 | 0.92 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL6317285 | 0.91 | DRD4 (0.85) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL29634880 | 0.91 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL6316908 | 0.91 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL4807347 | 0.87 | DRD4 (0.81) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL4807361 | 0.87 | DRD4 (0.81) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL6551097 | 0.86 | DRD4 (0.80) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6096279 | 0.80 | DRD4 (0.76) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL4809160 | 0.80 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960589-B2 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1483258-A1 | BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-07-01 | — | — | US | disclosed |
| WO-2003076431-A1 | BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | OPRK1 964/4885DRD4 2278/4885DRD2 2231/4885 |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | OPRK1 964/4885DRD4 2278/4885DRD2 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.